Secukinumab, an IL‐17A‐neutralizing antibody, is approved for a variety of inflammatory diseases (Langley et al., 2014) and has shown efficacy for multiple myeloma treatment in a preclinical study (Prabhala et al., 2016). This evidence concerns the gene IL17A and plasma cell myeloma.